AR125298A1 - Compuestos de oxoisoindolina sustituidos con piridinilo - Google Patents

Compuestos de oxoisoindolina sustituidos con piridinilo

Info

Publication number
AR125298A1
AR125298A1 ARP220100840A ARP220100840A AR125298A1 AR 125298 A1 AR125298 A1 AR 125298A1 AR P220100840 A ARP220100840 A AR P220100840A AR P220100840 A ARP220100840 A AR P220100840A AR 125298 A1 AR125298 A1 AR 125298A1
Authority
AR
Argentina
Prior art keywords
compounds
oxoisoindoline
pyridinyl
substituted
ch2f
Prior art date
Application number
ARP220100840A
Other languages
English (en)
Inventor
Yan Chen
Godwin Kwame Kumi
Audris Huang
Satheesh Kesavan Nair
Bharat Dinkar Shimpukade
Suresh Babu Vishwa Krishna Penmetsa
James Aaron Balog
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR125298A1 publication Critical patent/AR125298A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Se describen compuestos de la fórmula (1), o una sal del mismo, en donde: R¹ es -NH₂ o -NH(CH₃); cada R² es independientemente F, Cl, -CN, alquilo C₁₋₄, -CH₂F, -CHF₂, -CF₃, -OCH₃, o ciclopropilo; cada R⁴ es independientemente F, Cl, -CH₃, -CH₂F, -CHF₂, -CF₃, o -OCH₃; R⁶ es hidrógeno, alquilo C₁₋₂, o fluoroalquilo C₁₋₂; m es cero, 1, 2, o 3; y n es cero, 1, 2, o 3; con la condición de que cuando R⁶ es hidrógeno m es 1, 2 o 3. También se describen métodos para usar tales compuestos para inhibir la proteína Helios y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son útiles en el tratamiento de infecciones virales y trastornos proliferativos, como el cáncer.
ARP220100840A 2021-04-06 2022-04-05 Compuestos de oxoisoindolina sustituidos con piridinilo AR125298A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202111016193 2021-04-06
IN202111022098 2021-05-17

Publications (1)

Publication Number Publication Date
AR125298A1 true AR125298A1 (es) 2023-07-05

Family

ID=81385129

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100840A AR125298A1 (es) 2021-04-06 2022-04-05 Compuestos de oxoisoindolina sustituidos con piridinilo

Country Status (14)

Country Link
US (2) US11718601B2 (es)
EP (1) EP4320112A1 (es)
JP (1) JP2024515243A (es)
KR (1) KR20230165815A (es)
AR (1) AR125298A1 (es)
AU (1) AU2022253242A1 (es)
BR (1) BR112023020077A2 (es)
CA (1) CA3214244A1 (es)
CL (1) CL2023002966A1 (es)
CO (1) CO2023013321A2 (es)
IL (1) IL307343A (es)
PE (1) PE20231941A1 (es)
TW (1) TW202304881A (es)
WO (1) WO2022216644A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2624949C (en) 1996-07-24 2011-02-15 Celgene Corporation Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
CA2457319C (en) 2001-08-06 2011-07-05 The Children's Medical Center Corporation Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
EA026785B1 (ru) 2005-05-10 2017-05-31 Инсайт Холдингс Корпорейшн Модуляторы индоламин 2,3-диоксигеназы и способы их применения
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2009009116A2 (en) 2007-07-12 2009-01-15 Tolerx, Inc. Combination therapies employing gitr binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CA2707308C (en) 2007-11-30 2016-08-02 Newlink Genetics Corporation Ido inhibitors
WO2009137095A2 (en) 2008-05-08 2009-11-12 The Johns Hopkins University Compositions and methods for modulating an immune response
JP2011523616A (ja) 2008-05-29 2011-08-18 サン−ゴバン サントル ドゥ ルシェルシェ エ デトゥードゥ ユーロペン チタン酸アルミニウムを含有する多孔質構造体
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
SG196798A1 (en) 2008-12-09 2014-02-13 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5561577B2 (ja) 2009-07-01 2014-07-30 国立大学法人 名古屋工業大学 光学活性３’−フルオロサリドマイド誘導体の製造方法
RU2646139C1 (ru) 2009-09-03 2018-03-01 Мерк Шарп И Доум Корп. Анти-gitr-антитела
ES2601226T3 (es) 2009-10-28 2017-02-14 Newlink Genetics Corporation Derivados de imidazol como inhibidores de IDO
CN102791738B (zh) 2009-12-10 2015-10-07 霍夫曼-拉罗奇有限公司 优先结合人csf1r胞外域4的抗体及其用途
PL2542256T3 (pl) 2010-03-04 2020-01-31 Macrogenics, Inc. Przeciwciała reaktywne wobec b7-h3, ich immunologicznie czynne fragmenty i ich zastosowania
EP2542588A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
EP2542587A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
SG10201506906VA (en) 2010-09-09 2015-10-29 Pfizer 4-1bb binding molecules
NO2694640T3 (es) 2011-04-15 2018-03-17
ES2669310T3 (es) 2011-04-20 2018-05-24 Medimmune, Llc Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
PT2785375T (pt) 2011-11-28 2020-10-29 Merck Patent Gmbh Anticorpos anti-pd-l1 e usos destes
JP6242804B2 (ja) 2011-12-15 2017-12-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20220162819A (ko) 2012-05-11 2022-12-08 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN104684582A (zh) 2012-08-31 2015-06-03 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2015107196A1 (en) 2014-01-20 2015-07-23 Institut Curie Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation
WO2016191178A1 (en) 2015-05-22 2016-12-01 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
BR112017025975B1 (pt) 2015-06-04 2023-12-12 Arvinas Operations, Inc Composto, composição, método in vitro para induzir degradação de uma proteína alvo em uma célula, e, uso de uma composição
GB201516243D0 (en) 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2017117118A1 (en) 2015-12-28 2017-07-06 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
CA3017740A1 (en) 2016-03-16 2017-09-21 Pearlie BURNETTE Small molecules against cereblon to enhance effector t cell function
RU2021102253A (ru) 2016-04-06 2021-03-03 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка mdm2
AU2017254711B2 (en) 2016-04-22 2021-01-21 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
AU2017326171B2 (en) 2016-09-13 2021-12-09 The Regents Of The University Of Michigan Fused 1,4-oxazepines as BET protein degraders
HRP20230414T1 (hr) 2016-10-11 2023-07-07 Arvinas Operations, Inc. Spojevi i postupci za ciljanu razgradnju androgenog receptora
KR20230127371A (ko) 2016-11-01 2023-08-31 아비나스 오퍼레이션스, 인코포레이티드 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
AU2017366693B2 (en) 2016-12-01 2021-04-01 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
AU2017382176A1 (en) 2016-12-21 2019-05-30 Biotheryx, Inc. Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
IL294423B2 (en) 2016-12-23 2024-01-01 Univ Yale Compounds and methods for targeted reduction of rapidly accelerated polypeptide fibrosarcoma
WO2018119441A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Egfr proteolysis targeting chimeric molecules and associated methods of use
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
US20200339704A1 (en) 2017-10-18 2020-10-29 James E. Bradner Compositions and methods for selective protein degradation
EP3743066A4 (en) 2018-01-26 2021-09-08 Yale University IMIDE BASED MODULATORS OF PROTEOLYSIS AND METHOD OF USE
EP3773576A4 (en) * 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
WO2019241271A1 (en) 2018-06-13 2019-12-19 Biotheryx, Inc. Fused thiophene compounds
AU2019301944B2 (en) 2018-07-10 2022-02-24 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020102195A1 (en) * 2018-11-13 2020-05-22 Biotheryx, Inc. Substituted isoindolinones
EP3897637A1 (en) 2018-12-20 2021-10-27 Novartis AG Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN113329792A (zh) 2019-02-15 2021-08-31 诺华股份有限公司 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
EA202192019A1 (ru) 2019-02-15 2021-11-02 Новартис Аг Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
US20230093099A1 (en) 2019-04-02 2023-03-23 Cullgen (Shanghai), Inc. Compounds and methods of treating cancers
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物

Also Published As

Publication number Publication date
CL2023002966A1 (es) 2024-02-23
CA3214244A1 (en) 2022-10-13
WO2022216644A1 (en) 2022-10-13
US20230303527A1 (en) 2023-09-28
JP2024515243A (ja) 2024-04-08
TW202304881A (zh) 2023-02-01
PE20231941A1 (es) 2023-12-05
US20220324840A1 (en) 2022-10-13
BR112023020077A2 (pt) 2023-11-14
AU2022253242A1 (en) 2023-11-23
EP4320112A1 (en) 2024-02-14
CO2023013321A2 (es) 2023-10-19
KR20230165815A (ko) 2023-12-05
US11718601B2 (en) 2023-08-08
IL307343A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
AR119731A1 (es) Inhibidores del inflamasoma nlrp3
AR094668A1 (es) Amidas como moduladores de canales de sodio
CY1121120T1 (el) Αρυλ- ή ετεροαρυλ-υποκατεστημενες ενωσεις βενζολιου
AR119424A1 (es) Derivados de 3-oxo-4h-quinoxalina y oxo-1h-naftiridina como inhibidores de parp
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
PE20181366A1 (es) Compuestos heterociclicos utiles como moduladores de factor de necrosis tumoral (tnf) alfa
EA201690545A1 (ru) Онколитические аденовирусы, несущие гетерологичные гены
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
BR112015005817A2 (pt) compostos de bis(fluoroalquil)-1,4-benzodiazepinona como inibidores de notch
AR092869A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
AR125298A1 (es) Compuestos de oxoisoindolina sustituidos con piridinilo
AR107928A1 (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
AR108223A1 (es) Derivados de 6-oxo-1,6-dihidro-piridin-3-il
AR104326A1 (es) Compuestos nucleósidos 5-sustituidos
AR120823A1 (es) Compuestos bicíclicos sustituidos útiles como activadores de células t
AR107032A1 (es) Inhibidores bicíclicos de pad4
CL2022000485A1 (es) Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
AR116114A1 (es) Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
AR106138A1 (es) Compuestos y métodos para inhibir jak
AR097325A1 (es) Pirroles anillados
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer